| dbo:abstract |
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. It was designated as a breakthrough therapy for breast cancer by the U.S. Food and Drug Administration (FDA) in October 2015. On 28 September 2017, it was approved for use in the United States by the FDA for the treatment of certain breast cancers. (en) Abemaciclib ist ein Arzneistoff zur Behandlung bestimmter Formen des Brustkrebses. Er ist ein Vertreter der neuen Wirkstoffklasse der Cyclin-abhängigen Kinase-Inhibitoren und ist oral wirksam. Die Zulassung in den USA erfolgte am 28. September 2017 im Rahmen des beschleunigten Zulassungsverfahrens der FDA (Break Through Therapy), in der Europäischen Union ein Jahr später am 27. September 2018. (de) アベマシクリブ (英語: abemaciclib）は、進行性または転移性乳癌での治療薬の一つ。イーライリリー社により開発されたサイクリン依存性キナーゼ (CDK4/CDK6) の選択的阻害薬である。製品名はベージニオ、Verzenio。 乳癌の画期的治療法として米国食品医薬品局 (FDA) に2015年10月指定された。 2017年9月28日にFDAにより米国内での乳癌での使用が承認された。日本では2018年11月20日薬価収載された。 (ja) Abemaciclib, comercializado sob as marcas Verzenio, Verzenios e Ramiven, é um medicamento para o tratamento de cancro da mama metastático ou em estádios avançados. Atua como inibidor seletivo das proteínas e . (pt) 截癌寧（Abemaciclib，商品名Verzenio、Verzenios和Ramiven）是一种用于治疗晚期或转移性乳癌的药物。它由礼来（Eli Lily）研發，作用為CDK4和CDK6的选择性抑制剂。 2015 年 10 月，它被美国食品和药物管理局（FDA）同意作為乳癌的breakthrough therapy。 2017 年 9 月 28 日，它被 FDA 批准在美国用于治疗某些乳癌病人。 (zh) |
| dbo:alternativeName |
Verzenio, Verzenios, others (en) |
| dbo:bioavailability |
45.000000 (xsd:float) |
| dbo:casNumber |
1231929-97-7 |
| dbo:chEMBL |
3301610 |
| dbo:drugbank |
DB12001 |
| dbo:fdaUniiCode |
60UAB198HK |
| dbo:kegg |
D10688 |
| dbo:pubchem |
46220502 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Abemaciclib.svg?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/abemaciclib |
| dbo:wikiPageID |
49040444 (xsd:integer) |
| dbo:wikiPageLength |
13932 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1119969326 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Non-small-cell_lung_carcinoma dbr:Blood_plasma dbr:Breast_cancer dbr:Ribociclib dbr:Rifampicin dbr:Cyclin-dependent_kinase_4 dbr:Cyclin-dependent_kinase_6 dbr:Leukopenia dbc:Fluoroarenes dbc:Isopropyl_compounds dbc:Piperazines dbr:Nausea dbr:Oral_administration dbr:Retinoblastoma_protein dbr:Eli_Lilly_and_Company dbr:Elimination_half-life dbr:Fulvestrant dbr:Anemia dbr:Apoptosis dbr:Letrozole dbr:Leuckart_reaction dbr:Progression-free_survival dbr:Buchwald–Hartwig_amination dbr:HER2 dbr:Fatigue_(medical) dbr:Anastrozole dbc:Benzimidazoles dbr:Drug_development dbr:Erlotinib dbr:Estrogen_receptor dbr:Food_and_Drug_Administration dbr:Breakthrough_therapy dbr:Palbociclib dbr:Cell_cycle dbc:Aminopyrimidines dbc:Pyridines dbc:Breakthrough_therapy dbc:Protein_kinase_inhibitors dbc:Eli_Lilly_and_Company_brands dbr:Ketoconazole dbr:Bioavailability dbr:CDK_inhibitor dbr:CYP3A4 dbr:Placebo dbr:Reductive_amination dbr:Hydroxyl dbr:Medication dbr:Neutropenia dbr:Phases_of_clinical_research dbr:Phosphorylation dbr:Thrombocytopenia dbr:First_gap_phase dbr:Synthesis_phase dbr:Human_epidermal_growth_factor_receptor_2 dbr:Plasma_protein dbr:CDK4 dbr:CDK6 dbr:Oxidative dbr:Primary_endpoint dbr:Suzuki_coupling dbr:File:Abemaciclib_metabolite.svg |
| dbp:atcPrefix |
L01 (en) |
| dbp:atcSuffix |
EF03 (en) |
| dbp:bioavailability |
45.0 |
| dbp:c |
27 (xsd:integer) |
| dbp:casNumber |
1231929 (xsd:integer) |
| dbp:chembl |
3301610 (xsd:integer) |
| dbp:chemspiderid |
29340700 (xsd:integer) |
| dbp:dailymedid |
Abemaciclib (en) |
| dbp:drugbank |
DB12001 (en) |
| dbp:eliminationHalfLife |
65880.0 |
| dbp:excretion |
81 (xsd:integer) |
| dbp:f |
2 (xsd:integer) |
| dbp:h |
32 (xsd:integer) |
| dbp:iupacName |
N-[5-[methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1--1H-benzimidazol-6-yl]-2-pyrimidinamine (en) |
| dbp:kegg |
D10688 (en) |
| dbp:legalCa |
Rx-only / Schedule D (en) |
| dbp:legalEu |
Rx-only (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:n |
8 (xsd:integer) |
| dbp:pdbLigand |
6 (xsd:integer) |
| dbp:proteinBound |
96.3 |
| dbp:pubchem |
46220502 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Oral_administration |
| dbp:smiles |
CCN1CCNCc2cccNc3nccF (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
UZWDCWONPYILKI-UHFFFAOYSA-N (en) |
| dbp:synonyms |
LY2835219 (en) |
| dbp:tradename |
Verzenio, Verzenios, others (en) |
| dbp:unii |
60 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Chemotherapeutic_agents dbt:Cite_web dbt:IPAc-en dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Respell dbt:Short_description dbt:Use_dmy_dates dbt:Update_section dbt:Drugs.com |
| dcterms:subject |
dbc:Fluoroarenes dbc:Isopropyl_compounds dbc:Piperazines dbc:Benzimidazoles dbc:Aminopyrimidines dbc:Pyridines dbc:Breakthrough_therapy dbc:Protein_kinase_inhibitors dbc:Eli_Lilly_and_Company_brands |
| gold:hypernym |
dbr:Inhibitor |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. It was designated as a breakthrough therapy for breast cancer by the U.S. Food and Drug Administration (FDA) in October 2015. On 28 September 2017, it was approved for use in the United States by the FDA for the treatment of certain breast cancers. (en) Abemaciclib ist ein Arzneistoff zur Behandlung bestimmter Formen des Brustkrebses. Er ist ein Vertreter der neuen Wirkstoffklasse der Cyclin-abhängigen Kinase-Inhibitoren und ist oral wirksam. Die Zulassung in den USA erfolgte am 28. September 2017 im Rahmen des beschleunigten Zulassungsverfahrens der FDA (Break Through Therapy), in der Europäischen Union ein Jahr später am 27. September 2018. (de) アベマシクリブ (英語: abemaciclib）は、進行性または転移性乳癌での治療薬の一つ。イーライリリー社により開発されたサイクリン依存性キナーゼ (CDK4/CDK6) の選択的阻害薬である。製品名はベージニオ、Verzenio。 乳癌の画期的治療法として米国食品医薬品局 (FDA) に2015年10月指定された。 2017年9月28日にFDAにより米国内での乳癌での使用が承認された。日本では2018年11月20日薬価収載された。 (ja) Abemaciclib, comercializado sob as marcas Verzenio, Verzenios e Ramiven, é um medicamento para o tratamento de cancro da mama metastático ou em estádios avançados. Atua como inibidor seletivo das proteínas e . (pt) 截癌寧（Abemaciclib，商品名Verzenio、Verzenios和Ramiven）是一种用于治疗晚期或转移性乳癌的药物。它由礼来（Eli Lily）研發，作用為CDK4和CDK6的选择性抑制剂。 2015 年 10 月，它被美国食品和药物管理局（FDA）同意作為乳癌的breakthrough therapy。 2017 年 9 月 28 日，它被 FDA 批准在美国用于治疗某些乳癌病人。 (zh) |
| rdfs:label |
Abemaciclib (en) Abemaciclib (de) アベマシクリブ (ja) Abemaciclib (pt) 截癌寧 (zh) |
| owl:sameAs |
yago-res:Abemaciclib wikidata:Abemaciclib dbpedia-de:Abemaciclib dbpedia-fa:Abemaciclib dbpedia-hu:Abemaciclib dbpedia-ja:Abemaciclib http://or.dbpedia.org/resource/ଆବେମାସିକ୍ଲିବ dbpedia-pt:Abemaciclib dbpedia-sl:Abemaciclib dbpedia-vi:Abemaciclib dbpedia-zh:Abemaciclib https://global.dbpedia.org/id/2Fasd |
| prov:wasDerivedFrom |
wikipedia-en:Abemaciclib?oldid=1119969326&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Abemaciclib.svg wiki-commons:Special:FilePath/Abemaciclib_metabolite.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Abemaciclib |
| is dbo:wikiPageRedirects of |
dbr:C27H32F2N8 dbr:Abemacicilib dbr:Verzenio dbr:Verzenios dbr:LY2835219 dbr:Bemaciclib |
| is dbo:wikiPageWikiLink of |
dbr:List_of_drugs_granted_breakthrough_therapy_designation dbr:Epithelioid_sarcoma dbr:Liposarcoma dbr:C27H32F2N8 dbr:Abemacicilib dbr:Palbociclib dbr:Cell_cycle dbr:ATC_code_L01 dbr:Wafik_El-Deiry dbr:CDK_inhibitor dbr:Richard_Gaynor dbr:Verzenio dbr:Verzenios dbr:LY2835219 dbr:Bemaciclib |
| is foaf:primaryTopic of |
wikipedia-en:Abemaciclib |
